Program
mirikizumab
Also written as “Mirikizumab”, “LY3074828” and “Mirikizumab IV”.
Its studies are mostly in Colitis, Ulcerative · Psoriasis · Crohn Disease · Breast Feeding, led by 2 companies.
Drug pageMirikizumab: every studyAll 44 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 356 open or running | phase 4since May 21, 2026 | Sep 18, 2013 | Feb 2027phase 1 · NCT07446101 |
| Rubix LSits history only | 11 open or running | phase 4since Jul 1, 2025 | Jul 1, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 21 earlier studies, Sep 18, 2013 to Oct 22, 2019.
- Jun 9, 2017Named mirikizumabINNProposed as its International Nonproprietary Name in WHO's List 117 · before, LY3074828
- Jan 15, 2020Phase 3 study in Crohn DiseaseNCT04232553 · 996 enrolled · United States, Argentina, Australia and more
- Jul 10, 2020Phase 3 study in Colitis, UlcerativeNCT04469062
- Sep 10, 2020Phase 1 study in HealthyNCT04548219 · 60 enrolled · United States
- Oct 28, 2020Phase 1 study in HealthyNCT04607733 · 240 enrolled · United States
- Apr 12, 2021Phase 3 study in Colitis, UlcerativeNCT04844606 · 150 planned · United States, Austria, Belgium and more
- Oct 1, 2021Phase 1 study in HealthyNCT05069896 · 237 enrolled · United States
- Aug 19, 2022Phase 3 study in Crohn DiseaseNCT05509777 · 90 planned · United States, Austria, Belgium and more
- Aug 24, 2022Phase 1 study in HealthyNCT05515601 · 396 enrolled · United States
- Dec 1, 2022Phase 1 study in HealthyNCT05644353 · 450 enrolled · United States
- Feb 8, 2023Phase 3 study in Colitis, UlcerativeNCT05767021 · 172 enrolled · United States, Belgium, Czechia and more
- Mar 13, 2023Phase 3 study in Colitis, UlcerativeNCT05784246 · 63 enrolled · United States, Belgium, Canada and more
- Jun 21, 2024Phase 1 study in HealthyNCT06475729 · 498 enrolled · United States
- Feb 26, 2026Phase 1 study in HealthyNCT07446101 · 450 planned · United States
- May 21, 2026Phase 4 study in Breast FeedingNCT07612267 · 14 planned · United States, Canada, Denmark and more
Ahead
- Feb 2027Primary completion: phase 1 study in HealthyNCT07446101
- Dec 2027Primary completion: phase 3 study in Crohn DiseaseNCT05509777
- Sep 2028Primary completion: phase 4 study in Breast FeedingNCT07612267
- Dec 2030Primary completion: phase 3 study in Colitis, UlcerativeNCT04844606
TargetBeta
“Interleukin-23 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| risankizumabrule | AbbVie | phase 4 | 68 |
| guselkumabrule | Johnson & Johnson | phase 4 | 60 |
Studies
All 35 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07612267Breast Feeding · United States, Canada, Denmark and more | 4 | Recruiting | Sep 2028 | 14 |
| NCT07446101Healthy · United States | 1 | Recruiting | Feb 2027 | 450 |
| NCT06475729Healthy · United States | 1 | Completed | Dec 27, 2024 | 498 |
| NCT05784246Colitis, Ulcerative · United States, Belgium, Canada and more | 3 | Completed | May 1, 2026 | 63 |
| NCT05767021Colitis, Ulcerative · United States, Belgium, Czechia and more | 3 | Completed | Aug 9, 2024 | 172 |
| NCT05644353Healthy · United States | 1 | Completed | May 25, 2023 | 450 |
| NCT05515601Healthy · United States | 1 | Completed | Feb 20, 2023 | 396 |
| NCT05509777Crohn Disease · United States, Austria, Belgium and more | 3 | Recruiting | Dec 2027 | 90 |
| NCT05069896Healthy · United States | 1 | Completed | Jun 22, 2022 | 237 |
| NCT04844606Colitis, Ulcerative · United States, Austria, Belgium and more | 3 | Recruiting | Dec 2030 | 150 |
| NCT04607733Healthy · United States | 1 | Completed | May 17, 2021 | 240 |
| NCT04548219Healthy · United States | 1 | Completed | Jan 11, 2021 | 60 |
| NCT04469062Colitis, Ulcerative | 3 | Withdrawn | Mar 13, 2024 | 0 |
| NCT04232553Crohn Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Nov 28, 2024 | 996 |
| NCT04137380Healthy · China | 1 | Completed | Dec 11, 2020 | 60 |
| NCT04004611Colitis, Ulcerative · United States, Canada, Israel and more | 2 | Completed | Mar 15, 2023 | 26 |
| NCT03926130Crohn Disease · United States, Argentina, Australia and more | 3 | Completed | Aug 23, 2023 | 1,158 |
| NCT03718884Psoriasis · United States | 1 | Completed | Oct 28, 2019 | 29 |
| NCT03748940Healthy · United Kingdom | 1 | Completed | Jun 18, 2019 | 60 |
| NCT03662100Healthy · United States | 1 | Completed | Jan 25, 2019 | 66 |
| NCT03556202Psoriasis · United States, Argentina, Australia and more | 3 | Terminated | Feb 7, 2022 | 1,936 |
| NCT03535194Psoriasis · United States, Argentina, Australia and more | 3 | Completed | Mar 5, 2020 | 1,484 |
| NCT03524092Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Nov 3, 2021 | 1,328 |
| NCT03519945Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 4, 2026 | 1,058 |
| NCT03518086Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Jan 21, 2021 | 1,281 |
| NCT03482011Psoriasis · United States, Germany, Japan and more | 3 | Completed | Mar 21, 2019 | 530 |
| NCT03456713Healthy · United States | 1 | Completed | Aug 13, 2018 | 72 |
| NCT03220126Healthy · United Kingdom | 1 | Completed | Feb 23, 2018 | 72 |
| NCT03188510Healthy · United States | 1 | Completed | Nov 27, 2017 | 54 |
| NCT03053622Healthy · United Kingdom | 1 | Completed | Apr 3, 2018 | 67 |
| NCT02899988Plaque Psoriasis · United States, Canada, Germany and more | 2 | Completed | Jun 19, 2017 | 205 |
| NCT02891226Crohn Disease · United States, Australia, Belgium and more | 2 | Completed | Dec 11, 2018 | 191 |
| NCT02589665Colitis, Ulcerative · United States, Australia, Belgium and more | 2 | Completed | Dec 19, 2017 | 249 |
| NCT02568423Healthy · United States | 1 | Completed | Jul 16, 2018 | 51 |
| NCT01947933Psoriasis · Canada | 1 | Completed | Feb 2015 | 45 |
How it is read
Names in the registry
- “Mirikizumab”, 24 entries
- “LY3074828”, 6 entries
- “Mirikizumab IV”, 3 entries
- “Mirikizumab SC”, 3 entries
- “Mirikizumab - SC”, 3 entries
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 9 studies
- Psoriasis, 6 studies
- Crohn Disease, 5 studies
- Breast Feeding, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.